Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial

Zeitschrift fur Kardiologie

Volumn 89, Issue SUPPL. 4, 2000, Pages

  Zeymer, U ^a   Neuhaus, K L ^a  

^a KLINIKUM KASSEL   (Germany)

Author keywords

Acute myocardial infarction; Adjunctive therapy; Direct PTCA; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HIRUDIN; LAMIFIBAN; LANOTEPLASE; RETEPLASE; SARUPLASE; THROMBIN INHIBITOR;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ARTERY BLOOD FLOW; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CORONARY ARTERY; CORONARY REPERFUSION; FIBRINOLYTIC THERAPY; HUMAN; MORTALITY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT CONTRAINDICATION;

EID: 0034055125     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070061     Document Type: Article

References (66)

1. Herrick JB (1912) Clinical features of sudden obstruction of the coronary arteries. JAMA 59: 2015-2020
2. DeWood M, Spores J, Notske R et al. (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303: 897-901
3. Fletcher AP, Sherry S, Alkjaersig N et al. (1959) The maintenance of a sustained thrombolytic state in man: II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 38: 11-19
4. Yusuf S, Collins R, Peto R et al. (1985) Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials. Eur Heart J 6: 556-585
5. Chazov EL, Mateeva LS, Mazaer AV et al. (1976) Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter Arkh 48: 8-19
6. Rentrop KP, Blanke H, Karsch KR et al. (1981) Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 63: 307-312
7. Neuhaus KL, Köstering H, Tebbe U et al. (1981) Intravenöse Kurzzeit-Streptokinase-Therapie beim frischen Myokard-infarkt. Z Kardiol 70: 791-796
8. Schröder R, Biamino G, von Leitner ER et al. (1983) Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 67: 536-548
9. GISSI (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i: 397-401
10. ISIS-2 Collaborative Group (1988) Randomized trial of intravenons streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction. Lancet 2: 349-360
11. Fibrinolytic Therapy Trialists' (FTT) collaborative group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbitidy results from all randomised trials of more than 1000 patients. Lancet 343: 311-322
12. Cannon CP (1998) Time to treatment of acute myocardial infarction revisited. Current Opinion in Cardiology 13: 254-266
13. TIMI IIIB-Investigators (1994) Early effects of tissue-type plasminogen activator and a comparison invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI-IIIB trial. Circulation 89: 1545-1556
14. Neuhaus KL, von Essen R, Tebbe U et al. (1992) Improved thrombolysis in acute myo-cardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 19: 885-891
15. The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329: 1615-1620
16. The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673-682
17. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U (1989) Improved thrombolysis with a modified regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 14: 1566-1569
18. Zeymer U, Neuhaus KL (1998) New thromholytic agents. In: Cannon CP (ed) Management of Acute Coronary-Syndromes. Humana Press, Totowa, USA, pp 243-265
19. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD, for the RAPID-II Investigators (1996) Randomized comparison of coronary thrombolysis avchieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 94: 891-898
20. The GUSTO III Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337: 1118-1123
21. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennell W, Betriu A, Ruda M, Mlezoch J (1998) Randomized, double-blind comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 31: 487-493
22. Bär FW, Hopkins G (1998) The bolus versus infusion in rescuepase (saruplase) development (BIRD) study in 2410 patients with acute myocardial infarction. Circulation 98, Suppl I: I-505
23. Den Heijer P, Vermeer F, Ambrsioni E, Sadowski Z, Lopez-Sendon JL, von Essen R, Beaufils P, Thadani U, Adgey J, Pierard L, Brinker J, Davies RF, Smalling RW, Wallentin L, Caspi A, Pangerl A, Trickett L, Hauck C, Henry D, Chew P, on behalf of the InTIME Investigators (1998) Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 98: 2117-2125
24. th
25. Cannon CP, McCabe CH, Gibson M et al. (1997) TNK-tisssue plasminogen activator in acute yocardial infarction. Result of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial. Circulation 95: 351-356
26. Cannon CP, Gibson M, McCabe CH et al. (1998) TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial. Circulation 98: 2805-2814
27. Van de Werf F, Cannon CP, Luyten A et al. (1999) Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 137: 786-791
28. th
29. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326: 242-250; 326: 310-318
30. Cannon CP, McCabe CH, Henry TD et al. (1994) A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 23: 993-1003
31. von Essen R, Zeymer U, Tebbe U, Jessel A, Kwasny H, Mateblowski M, Niederer W, Wagner J, Mäurer W, von Leitner ER, Haerten K, Roth M, Neuhaus KL, for the ALKK (1998) HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte. Coronary Artery Dis 9: 265-272
32. Zeymer U, Neuhaus KL (1995) Hirudin and excess bleeding: Implications for future use. Drug Safety 12: 234-239
33. Antman EM for the TIMI 9A Investigators (1994) Hirudin in acute myocardial infarction. Circulation 90: 1624-1630
34. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ, for the GUSTO-IIb Invstigators (1998) Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. J Am Coll Cardiol 31: 1493-1498
35. Neuhaus KL, Molhoek GP, Zeymer U, Tebbe U, Wegscheider K, Schröder R, Camez A, Laarman GJ, Grollier GM, Lok DJA, Kuckuck H, Lazarus P, for the HIT-4 Investigators (1999) Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4-trial. J Am Coll Cardiol 34: 966-973
36. Zeymer U, Mateblowski M, Neuhaus KL (1996) Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction. Eur Heart J 17: 1836-1840
37. Zeymer U (1998) Recombinant hirudins. An overview of recent developments. Bio-Drugs 10: 425-436
38. Topol EJ (1998) Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 97: 211-218
39. Van den Merckhoh LFM, Zijlstra F, Olsson H et al. (1999) Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study. J Am Coll Cardiol 33: 1528-1532
40. Amman EM, Giugliano RP, Gibson M, McCabe CH, Coussement P, Kleiman N, Vahanian A, Adgey AAJ, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the TIMI 14 Investigators (1999) Abciximab facilitates the rate and extent of thrombolysis. Results of the TIMI 14 trial. Circulation 99: 2720-2732
41. Ohman EM, Lincoff AM, Bode C, Bachinsky WB, Ardissino D, Matteo S, Betriu A, Schildcrout S, Barnathan E, Sherer J, Sketch MS, Topol EJ (1998) Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-4 (SPEED) dose-ranging trial. Circulation 98, Suppl I: I-504
42. Kleiman NS, Ohman EM, Califf RM et al. (1993) Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy: results of the TAMI 8 pilot study. J Am Coll Cardiol 22: 381-389
43. Ohman EM, Kleiman NS, Gacioch G, for the IMPACT-AMI Investigators (1997) Combined accelerated tissue plasminogen activator and platelet glycoprotein IIb/IIIa integrin blockade with integrilin in acute myocardial infarction: results from a randomized, placebo-controlled, dose-ranging trial. Circulation 95: 846-854
44. Ronner E, van Kasteren HAM, Zijnen P, Tebbe U, Molhoek P, Cuffie C, Neuhaus KL, Simoons M (1998) Combined therapy with streptokinase and integrilin. J Am Coll Cardiol 31, Suppl A: 191A
45. The PARADIGM Investigators (1998) Combining thrombolysis with the glycoprotein IIb/IIIa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Cardiol 32: 2003-2010
46. Hartzler GO, Rutherford BD, McConahay DR (1983) Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarc-tion. Am Heart J 106: 965-973
47. Grines CL, Browne KF, Marco J, Rothbaum, D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chellioh N, Timmis GC (1993) A comparison of immediate angioplasty with thrombolytic therapy for acute myocar-dial infarction. N Engl J Med 328: 673-679
48. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reibers JHC, Suryaranata H (1993) A comparison of immediate angioplasty with intravenous streptokinase in acute myocardial in-farction. N Engl J Med 328: 680-684
49. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspieger MR, Gersh BJ (1993) Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative therapy for myocardial infarction. N Engl J Med 328: 685-691
50. Vogt A, Neuhaus KL (1999) The German experience with primary angioplasty. Semin Intervent Cardiol: 543-546
51. Gusto IIb angioplasty substudy investigators (1997) A clinical trial comparing primary coronary angioplasty with tisue plasminogen activator for acute myocardial infarction. N Engl J Med 336: 1621-1628
52. Every N, Parsons LS, Hlatky M, Martin JS, Weaver WD, for the MITI Investigators (1996) A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 335: 1253-1260
53. Weaver WD, Simes J, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfield L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F et al. (1997) Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. JAMA 278: 2093-2098
54. Granger CB, Betriu A, Phillips HR, Stebbins AL, Califf RM (1997) Nearly half of the early benefit of direct angioplasty is lost in longer-term follow-up. 6-month results from the GUSTO-IIb direct angioplasty substudy. Circulation 96, Suppl I: I-205
55. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ (1998) Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction. J Am Coll Cardiol 31: 1240-1245
56. TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 312: 932-936
57. Fath-Ordoubadi F, Huehns TY, Al-Mohammed A, Beatt KJ (1997) Significance of the TIMI scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J 134: 62-68
58. Califf RM, O'Neil W, Stack RS et al. (1988) Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Int Med 108: 658-662
59. Schröder R, Dissmann R, Brüggemann T, Wegscheider K, Linderer T, Tebbe U, Neuhaus KL (1994) Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 24: 384-391
60. Schröder R, Wegscheider K, Schröder K, Dissmann R, Meyer-Sabellek W, for the INJECT Trial Group (1995) Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. J Am Coll Cardiol 26: 1657-1664
61. Schröder R, Zeymer U, Wegscheider K, Neuhaus KL (1999) Predictive value of ST segment elevation resolution 90 and 180 minutes after start of streptokinase in acute myocardial infarction. A substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 study. Eur Heart J 24: 1563-1571
62. Neuhaus KL, Zeymer U, Tebbe U, Schröder R (1998) Resolution of ST segment elevation is an early predictor of mortality in patients with acute myocardial infarction. Meta analysis of three thrombolysis trials. Circulation 98, Suppl I: I-632
63. van 't Hof AWJ, Liem A, de Boer MJ, Zijlstra F, for the Zwolle Myocardial Infarction Study Group (1997) Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 350: 615-619
64. Ellis SG, van de Werf F, Ribeiro da Silva E, Topol EJ (1992) Present status of rescue coronary angioplasty: current polarization of opinion and randomized trials. J Am Coll Cardiol 19: 681-686
65. McKendall GR, Forman S, Sopko G, Braunwald E, Williams DO, and the TIMI Investigators (1995) Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 76: 1108-1111
66. Ellis SG, Ribeiro da Silva E, Heyndrickx G et al. (1994) Randomized comparison of rescue angioplasty with conservative managment of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 90: 2280-2284